Cardiol TherapeuticsCRDL +2.42%34 Market Cap is $120.98 Mil as of Jun. 30, 2026. GuruFocus rates CRDL with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Cardiol Therapeutics ranks worse than 57.25% on this metric.
Cardiol Therapeutics's quarterly market cap
increased
from Sep. 2025 ($93.58 Mil) to Dec. 2025 ($95.63 Mil) and
increased
from Dec. 2025 ($95.63 Mil) to Mar. 2026 ($151.03 Mil).
Cardiol Therapeutics's annual market cap
increased
from Dec. 2023 ($55.10 Mil) to Dec. 2024 ($105.74 Mil) but then
declined
from Dec. 2024 ($105.74 Mil) to Dec. 2025 ($95.63 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cardiol Therapeutics's Enterprise Value for Today is $104.49 Mil.
Cardiol Therapeutics (NAS:CRDL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cardiol Therapeutics Market Cap Related Terms
Cardiol Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Cardiol Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiol Therapeutics Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Cardiol Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cardiol Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiol Therapeutics (CRDL) has a Market Cap of $120.98 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cardiol Therapeutics and its competitors. According to the industry distribution chart, Cardiol Therapeutics ranks #584 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 57.3%.
Is Cardiol Therapeutics' Market Cap too high?
Cardiol Therapeutics' current Market Cap is $120.98 Mil. The Drug Manufacturers industry median Market Cap is 213.67. Cardiol Therapeutics' value of $120.98 Mil is 43.4% below this industry median. Based on the distribution chart, Cardiol Therapeutics ranks #584 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cardiol Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #584 out of 1020 companies for Market Cap. This places Cardiol Therapeutics in the lower half of its industry. The industry median Market Cap is 213.67. Cardiol Therapeutics' value of $120.98 Mil is 43.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.67, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiol Therapeutics's current Market Cap of $120.98 Mil is 43.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cardiol Therapeutics and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiol Therapeutics's current Market Cap is $120.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (CRDL) has a current Market Cap of $120.98 Mil. The current Market Cap is $120.98 Mil and 43.4% below the Drug Manufacturers industry median of 213.67. Cardiol Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cardiol Therapeutics (CRDL), the current Market Cap is $120.98 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
34GF Score
Get the complete analysis for CRDL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDL has been successfully added to your 
